Hemoperfusion Cartridge Market By Product Type/Adsorbent Material (Resin-Based Hemoperfusion Cartridges, Activated Carbon Hemoperfusion Cartridges, Polymyxin B-Immobilized Cartridges, Other Specialized Adsorption Cartridges); By Application (Sepsis & Septic Shock, Acute & Chronic Kidney Disease, Liver Failure, Drug Overdose & Poisoning, Cytokine Removal & Inflammatory Conditions, Other Applications); By Treatment Modality (Standalone Hemoperfusion, Hemoperfusion Combined with Hemodialysis, Hemoperfusion Combined with Continuous Renal Replacement Therapy [CRRT], Hemoperfusion Combined with Plasma-Based Therapies); By End User (Hospitals, Dialysis Centers, Specialty Clinics, Emergency & Critical Care Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Advanced Blood Purification Technologies Transforming the Hemoperfusion Cartridge Market? – (Updated On: 12th-Oct-2026)

The Global Hemoperfusion Cartridge Market was valued at USD 447.4 million in 2025 and is projected to reach USD 723.1 million by 2032, expanding at an estimated CAGR of 7.1% during 2026–2032.

 

Hemoperfusion cartridges are disposable blood purification devices used to remove selected drugs, toxins, and inflammatory substances from a patient's blood.

 

Clinical adoption is established in several international markets. CytoSorbents reported more than 300,000 cumulative CytoSorb treatments worldwide by the end of 2025, with distribution across more than 70 countries. Toray Medical's TORAYMYXIN cartridge, designed to remove bacterial endotoxins from blood, has been used to treat more than 150,000 patients globally.

 

Manufacturers are developing cartridges for different clinical applications. Jafron Biomedical's HA330 and HA380 use resin-based adsorption technology to remove selected toxins and inflammatory substances. CytoSorb targets substances including inflammatory cytokines, bilirubin, and myoglobin, while TORAYMYXIN focuses on endotoxin removal in selected patients with sepsis or septic shock. CytoSorbents' DrugSorb-ATR is being investigated in the United States for removing certain blood-thinning medicines during cardiac surgery. Its clinical program included 140 randomized patients, although the device has not received FDA clearance or approval.

 

The market is increasingly shaped by application-specific cartridges, clinical evidence, regulatory approvals, and compatibility with existing hospital blood purification systems. Disposable cartridge consumption creates recurring demand, while adoption depends on demonstrated patient benefits and treatment guidelines. Evidence remains uncertain for routine hemoperfusion in sepsis, making severe poisoning, established specialized applications, and validated clinical indications particularly important when assessing future market opportunities.

 

Which Hemoperfusion Cartridge Segments Lead the Market, and Which Are Emerging as the Fastest-Expanding Categories?

By Product Type: Resin-Based Cartridges Lead Revenue as Specialized Adsorption Applications Expand

Largest and Fastest-Growing Subsegment — Resin-Based Hemoperfusion Cartridges

Resin-based hemoperfusion cartridges accounted for an estimated 53% of the global market, valued at USD 237.12 million in 2025, and are projected to grow at a CAGR of 7.63% during 2026–2032. Using synthetic polymer materials such as polystyrene-based and neutral macroporous resins, the cartridges remove toxins, drugs, and inflammatory mediators directly from whole blood through adsorption. Their established use in poisoning management, critical care, and extracorporeal blood purification supports continued adoption across hospitals and specialized treatment centers worldwide over the forecast period.

 

By Application: Sepsis Treatment Leads Revenue While Cytokine Removal Offers Faster Expansion

Largest Subsegment — Sepsis and Septic Shock

Sepsis and septic shock represented approximately 30% of the global Hemoperfusion Cartridges Market, accounting for USD 134.22 million in 2025, with a projected CAGR of 8.05% during 2026–2032. Hemoperfusion cartridges are increasingly used as adjunctive extracorporeal blood purification therapies in critically ill patients, helping remove circulating inflammatory mediators and potentially support immune and hemodynamic stability. The growing incidence of severe infections, rising intensive care admissions, and increasing clinical interest in cytokine adsorption therapies are supporting greater adoption of hemoperfusion cartridges in sepsis management worldwide.

Fastest-Growing Subsegment — Cytokine Removal and Inflammatory Conditions

Cytokine removal and inflammatory conditions accounted for an estimated 13% share of the global Hemoperfusion Cartridges Market, valued at approximately USD 58.16 million in 2025, and are projected to register the fastest CAGR of 8.25% during 2026–2032. Hemoperfusion cartridges help remove circulating inflammatory mediators from the bloodstream, supporting the management of severe systemic inflammation and cytokine storms. Increasing clinical interest in extracorporeal blood purification for sepsis, critical care, and severe inflammatory complications is supporting wider adoption of specialized hemoperfusion cartridges in intensive care settings.

 

By Treatment Modality: Hemodialysis Integration Dominates While CRRT Combinations Accelerate

Largest Subsegment — Hemoperfusion Combined with Hemodialysis

Hemoperfusion combined with hemodialysis accounted for an estimated 37% of the global Hemoperfusion Cartridges Market, valued at USD 165.54 million in 2025, and is projected to grow at a CAGR of 6.48% during 2026–2032. Integrating hemoperfusion cartridges with conventional hemodialysis enables the removal of a broader range of toxins and harmful substances than dialysis alone. Increasing clinical adoption of combined extracorporeal therapies for severe poisoning, kidney-related complications, and complex critical care conditions supports cartridge utilization across hospitals and specialized dialysis centers worldwide.

Fastest-Growing Subsegment — Hemoperfusion Combined with CRRT

Hemoperfusion combined with continuous renal replacement therapy (CRRT) accounted for an estimated 34% of the global Hemoperfusion Cartridges Market, valued at USD 152.12 million in 2025, and is projected to register the fastest CAGR of 8.78% during 2026–2032. The combination supports advanced blood purification by removing inflammatory mediators, endotoxins, and protein-bound toxins that conventional CRRT membranes may not adequately eliminate. Increasing clinical use in critical care, particularly for sepsis, acute kidney injury, and severe inflammatory conditions, supports broader adoption of specialized hemoperfusion cartridges.

 

By End User: Hospital Purchasing Leads as Emergency and Critical Care Demand Expands

Largest Subsegment — Hospitals

Hospitals held the largest estimated share of the Hemoperfusion Cartridges Market at 61%, representing USD 272.91 million in 2025, and are projected to grow at a CAGR of 7.08% during 2026–2032. Hospitals increasingly utilize hemoperfusion cartridges for extracorporeal blood purification to remove protein-bound toxins, fat-soluble substances, harmful drugs, and inflammatory cytokines from patients’ circulation. Rising cases of severe poisoning, critical illnesses, and complications requiring intensive care are supporting wider hospital adoption, particularly in emergency departments, intensive care units, and specialized nephrology centers.

Fastest-Growing Subsegment — Emergency and Critical Care Centers

Emergency and Critical Care Centers accounted for approximately 10% of the global Hemoperfusion Cartridges Market, valued at USD 44.74 million in 2025, and are projected to register the fastest CAGR of 8.88% during 2026–2032. Hemoperfusion cartridges are increasingly used in emergency settings for extracorporeal blood purification, helping remove circulating toxins, drug residues, and inflammatory mediators from the bloodstream. Rising cases of acute poisoning, drug overdoses, and severe inflammatory conditions are supporting wider adoption of hemoperfusion cartridges across emergency departments and critical care facilities worldwide.

 

By Region: Asia-Pacific Leads Global Revenue and Maintains the Fastest Growth Outlook

Largest and Fastest-Growing Region — Asia-Pacific

Asia-Pacific accounted for an estimated 40% market share, generating USD 178.96 million in 2025 revenue, and is projected to expand at a 7.61% CAGR during 2026–2032. Regional leadership reflects China's established hemoperfusion manufacturing base and application of resin-based cartridges in renal care. Jafron Biomedical contributes to regional production through its HA-series adsorption products, while Japanese manufacturers Toray Medical and Kaneka supply specialized endotoxin and protein adsorption technologies. China's large dialysis population and existing hospital distribution networks support recurring cartridge sales, making the region an important manufacturing and commercialization center.

 

How Are Leading Manufacturers, Specialized Adsorption Technologies, and Competitive Strategies Shaping the Hemoperfusion Cartridge Market?

Jafron Biomedical — Leading Resin-Based Hemoperfusion Cartridge Manufacturer

Jafron Biomedical is a major Chinese hemoperfusion cartridge manufacturer specializing in macroporous resin adsorption technology. Its HA-series disposable cartridges are used in blood purification applications involving kidney disease, liver failure, and selected critical care conditions. According to the company's disclosures, Jafron's hemoadsorption products are used in more than 8,000 hospitals across 99 countries and regions, with approximately 6 million clinical applications annually. The company also reports an annual manufacturing capacity of approximately 20 million hemoperfusion cartridges, highlighting its production scale. Its established dialysis integration and international distribution network support recurring cartridge sales and expansion into additional treatment markets.

CytoSorbents Corporation — Established Cytokine Adsorption Technology Provider

CytoSorbents specializes in porous polymer-based blood purification technology designed to adsorb inflammatory mediators and selected drugs from circulating blood. Its CytoSorb platform serves critical care and extracorporeal treatment applications, while DrugSorb-ATR targets drug removal during cardiac surgery. The company reported USD 37.1 million in product revenue in 2025, representing 4.1% year-over-year growth, with a 71.5% gross margin. Cumulative CytoSorb treatments exceeded 300,000 worldwide by January 2026. Germany generated approximately USD 11.8 million in 2025 sales, demonstrating the importance of established European markets. Its commercial presence and clinical development programs support further opportunities, although CytoSorb and DrugSorb-ATR remain investigational in the United States.

Other Important Manufacturers and Their Roles in Hemoperfusion Technology:

• Toray Medical (Japan): Manufactures TORAYMYXIN cartridges using polymyxin B-immobilized fibers to selectively adsorb bacterial endotoxins, serving the specialized sepsis and critical care blood purification market.

• Kaneka Corporation (Japan): Develops LIXELLE adsorption columns that remove beta-2-microglobulin in patients with dialysis-related amyloidosis, supporting specialized blood purification alongside hemodialysis.

• Efferon: Manufactures Efferon LPS cartridges using macroporous polymer adsorbents with selective endotoxin-binding ligands; the technology targets endotoxins and inflammatory mediators in critical care applications.

• Foshan Biosun Medical Technology (China): Produces MG-series disposable hemoperfusion cartridges using polymer adsorption beads for removing middle-to-large molecular toxins, with company-reported cumulative clinical use exceeding 4.58 million units.

 

Analyst Commentary: How Will Clinical Validation and Dialysis Integration Shape the Hemoperfusion Cartridge Market?

The Hemoperfusion Cartridge Market's next phase of growth will depend less on expanding cartridge availability and more on demonstrating measurable clinical benefits that justify routine use. Resin-based cartridges have established a commercial foundation in renal care, while cytokine and endotoxin adsorption technologies face greater scrutiny over treatment outcomes and cost-effectiveness. Integration with hemodialysis and CRRT offers manufacturers access to existing hospital infrastructure without requiring entirely new treatment platforms.

 

Hemoperfusion Cartridge Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 447.4 Million
Revenue Forecast in 2032	USD 723.1 Million
Overall Growth Rate	CAGR of 7.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type / Adsorbent Material, By Application, By Treatment Modality, By End User, By Geography
By Product Type / Adsorbent Material	Resin-Based Hemoperfusion Cartridges, Activated Carbon Hemoperfusion Cartridges, Polymyxin B-Immobilized Cartridges, Other Specialized Adsorption Cartridges
By Application	Sepsis and Septic Shock, Acute and Chronic Kidney Disease, Liver Failure, Drug Overdose and Poisoning, Cytokine Removal and Inflammatory Conditions, Other Applications
By Treatment Modality	Standalone Hemoperfusion, Hemoperfusion Combined with Hemodialysis, Hemoperfusion Combined with CRRT, Hemoperfusion Combined with Plasma-Based Therapies
By End User	Hospitals, Dialysis Centers, Specialty Clinics, Emergency and Critical Care Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing adoption of extracorporeal blood purification, increasing use of resin-based adsorption cartridges, rising demand for toxin and drug removal, expanding critical-care applications, growing integration of hemoperfusion with hemodialysis and CRRT, increasing interest in cytokine and endotoxin adsorption, development of application-specific cartridges, expansion of hospital blood purification infrastructure, and recurring demand for disposable hemoperfusion cartridges
Customization Option	Available upon request